296 related articles for article (PubMed ID: 7600086)
1. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
[TBL] [Abstract][Full Text] [Related]
2. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
3. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
[TBL] [Abstract][Full Text] [Related]
4. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
5. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
[TBL] [Abstract][Full Text] [Related]
6. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
7. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes.
Bäckman L; Robins-Wahlin TB; Lundin A; Ginovart N; Farde L
Brain; 1997 Dec; 120 ( Pt 12)():2207-17. PubMed ID: 9448576
[TBL] [Abstract][Full Text] [Related]
8. Neurochemical substrates of rigidity and chorea in Huntington's disease.
Storey E; Beal MF
Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
[TBL] [Abstract][Full Text] [Related]
9. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.
Turjanski N; Lees AJ; Brooks DJ
Neurology; 1997 Sep; 49(3):717-23. PubMed ID: 9305330
[TBL] [Abstract][Full Text] [Related]
10. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
Antonini A; Leenders KL; Eidelberg D
Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
[TBL] [Abstract][Full Text] [Related]
11. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
Glass M; Dragunow M; Faull RL
Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
[TBL] [Abstract][Full Text] [Related]
12. Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.
Tedroff J; Pedersen M; Aquilonius SM; Hartvig P; Jacobsson G; Långström B
Neurology; 1996 May; 46(5):1430-6. PubMed ID: 8628494
[TBL] [Abstract][Full Text] [Related]
13. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.
Farde L; Wiesel FA; Stone-Elander S; Halldin C; Nordström AL; Hall H; Sedvall G
Arch Gen Psychiatry; 1990 Mar; 47(3):213-9. PubMed ID: 1968328
[TBL] [Abstract][Full Text] [Related]
14. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride.
Rinne JO; Laihinen A; Ruottinen H; Ruotsalainen U; Någren K; Lehikoinen P; Oikonen V; Rinne UK
J Neurol Sci; 1995 Oct; 132(2):156-61. PubMed ID: 8543941
[TBL] [Abstract][Full Text] [Related]
15. Benzodiazepine receptor binding in Huntington's disease: [11C]flumazenil uptake measured using positron emission tomography.
Künig G; Leenders KL; Sanchez-Pernaute R; Antonini A; Vontobel P; Verhagen A; Günther I
Ann Neurol; 2000 May; 47(5):644-8. PubMed ID: 10805336
[TBL] [Abstract][Full Text] [Related]
16. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
[TBL] [Abstract][Full Text] [Related]
17. Bradykinesia in early Huntington's disease.
Sánchez-Pernaute R; Künig G; del Barrio Alba A; de Yébenes JG; Vontobel P; Leenders KL
Neurology; 2000 Jan; 54(1):119-25. PubMed ID: 10636136
[TBL] [Abstract][Full Text] [Related]
18. Right-left asymmetry of D1- and D2-receptor density is lost in the basal ganglia of old rats.
Giardino L
Brain Res; 1996 May; 720(1-2):235-8. PubMed ID: 8782918
[TBL] [Abstract][Full Text] [Related]
19. Nigral dopamine type-1 receptors are reduced in Huntington's disease: a postmortem autoradiographic study using [3H]SCH 23390 and correlation with [3H]forskolin binding.
Filloux F; Wagster MV; Folstein S; Price DL; Hedreen JC; Dawson TM; Wamsley JK
Exp Neurol; 1990 Nov; 110(2):219-27. PubMed ID: 2146140
[TBL] [Abstract][Full Text] [Related]
20. The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat.
Besret L; Page KJ; Dunnett SB
Brain Res; 2000 Jan; 853(1):125-35. PubMed ID: 10627316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
